🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

LUMINOSITY Data Continue to Highlight Utility of Telisotuzumab Vedotin in c-MET–Overexpressing NSCLC UCLA Jonsson Comprehensive Cancer Center #lcsm #oncology onclive.com/view/luminosit…

Delighted to present episode 2 of ESMO - Eur. Oncology Women4Oncology’s Diary of an Oncology Leader, with Chair of Thoracic Oncology Marina Garassino from UniversityofChicago Great insights on: - role of community in skill-building - self belief - thinking big ‘Don’t wait. Just start’ OncoAlert #LCSM

Important to remember that patients can only benefit if they are able to tolerate it and The #COCOON data shows that proactive management of side effects reduces them and increases #QOL That Matters! #TumorBoardTuesday #LCSM

This is a beautiful illustration by Julia Rotow MD But from discussions in our community, sequencing in routine clinic is more of an art than science. This emphasizes the importance of there is no one size fits all treatment approach - the right first line depends on preferences

SKIPPirr Study gilberto lopes et al. 👇🏽👇🏽

Great summary by Kelsey Pan, MD, MPH of tonight’s #TumorBoardTuesday discussion on the evolving frontline landscape for EGFR+ NSCLC—the meme doesn’t hurt 🤣 Oncology Brothers LungCancerRx 🫁💊 EGFR Resisters Jill Feldman

THIS ⬇️ Patients don’t experience side effects separately from survival, impact & #QOL. #TumorBoardTuesday #LCSM

Kelsey Pan, MD, MPH #TumorBoardTuesday Eric K. Singhi, MD Integrity CE, LLC Julia Rotow MD There is a lot happening in mEGFR space (this slide is amazing)! At the time of progression, HER3-Dxd likely won’t be available. Data-Dxd approval is pending (look forward to this but will need bigger/mature data here) Eric K. Singhi, MD Kelsey Pan, MD, MPH

Eric K. Singhi, MD Kelsey Pan, MD, MPH #TumorBoardTuesday Integrity CE, LLC Julia Rotow MD Oncology Brothers Jill Feldman With ivonescimab at least delayed and patritumab out of the game- MARIPOSA2 has a pretty solid landing in 2nd line post front-line osi (or afatinib for uncommon EGFR mutation+ nsclc) for now (and maybe also past FLAURA-2 for pts who have come off maintenance chemo a while back so

Balazs Halmos Eric K. Singhi, MD Kelsey Pan, MD, MPH #TumorBoardTuesday Integrity CE, LLC Julia Rotow MD Oncology Brothers Jill Feldman I agree that there is a role for amivantamab (either w TKI or chemo) after #FLAURA2 (if the chemo had been stopped) but in general, amivantamab benefit and tolerance is better on 1st line setting. Eric K. Singhi, MD

Eric K. Singhi, MD Kelsey Pan, MD, MPH #TumorBoardTuesday Integrity CE, LLC Julia Rotow MD Raffaele Califano EGFR Resisters Thank you Eric K. Singhi, MD, Proactive #toxicity management should be part of standard care when possible. Think of it like sunscreen: you apply it BEFORE going out in the sun, not wait until you are sunburned. It won't prevent every burn, but it can significantly reduce severity,

Eric K. Singhi, MD Kelsey Pan, MD, MPH #TumorBoardTuesday Integrity CE, LLC Julia Rotow MD Raffaele Califano EGFR Resisters Informed 1st. Shared 2nd. Patients need to clearly understand their options—the benefits, risks, and trade-offs of all treatment options. Only then can we engage in meaningful shared decision-making that respects our goals and values.

Dr. Alexander Drilon MD at #CIOT25 clearly favoring taletrectinib as 1L for #ROS1 NSCLC - potential and better tox profile. NVL-520 zidesamtinib poised to potentially be best in class. For #RET, after selpercatinib or pralsetinib, few options. EP0031 is one in development.

“The future of staging is molecular.” Key message from Anna McGuire MD MSc kicking off #ELIXR25. I emphatically agree. TNM is all anatomic, yet biology is king. TNM approximates both disease biology & duration of disease, but fails to address response to ever-improving therapies.

#ELIXR25🍁 Thought-provoking talk by Mara Antonoff, MD, FACS on whether staging should be based on biology rather than anatomy- YES! Supporting thoughts: - deferring prognosis evaluation until initial response to Tx - propose local Tx after systemic tx MD Anderson Cancer Center OncoAlert #LCSM

#ELIXR25🍁 Getting ready for the ‘Frenemies’ debate! Neoadj vs Periop ChemoIO in resectable NSCLC 🥊Tina Cascone🇺🇸 MD Anderson Cancer Center Versus 🥊Patrick Forde🇮🇪Trinity St James's Cancer Institute Let the games begin! OncoAlert #LCSM

Dr Cecilia Pompili MD PhD FACS provides an overview of patient-reported outcomes in perioperative trials at #ELIXR25. Definitions of patient-related factors for attrition from interventions varies among trials, making it challenging to assess collectively. We need standardization. #LCSM

Treatment for early-stage lung cancer can have long-term impact on patients, highlighted by Dr Jarushka Naidoo at #ELIXR25. Evidence from other malignancies shows that irAEs are common and may continue long after the studies end - we need data in this space for NSCLC.

Thank you to Dr. Nasser Hanna (Nasser Hanna IU Simon Comprehensive Cancer Center) & Dr. Michael Gieske (Michael Gieske, M.D. St. Elizabeth) for a wonderful SmallCellSMASHERS Fireside chat today on lung cancer screening! LUNGevity Foundation The White Ribbon Project™ Jeff Yang MD FACS Chris Draft Lecia Sequist, MD, MPH ALCSI Ann Steagall

Big news from JTO & JTO CRR! 📘 JTO Impact Factor: 20.8 🔹 #3 in Respiratory Medicine 🔹 #13 in Oncology A high-impact leader in thoracic oncology! 👏 for JTO CRR with an IF of 3.5, rising in both oncology & respiratory rankings! ➡️ bit.ly/3ZGbIol